Search

Your search keyword '"Poelstra, K"' showing total 147 results

Search Constraints

Start Over You searched for: Author "Poelstra, K" Remove constraint Author: "Poelstra, K" Database MEDLINE Remove constraint Database: MEDLINE
147 results on '"Poelstra, K"'

Search Results

1. Unrecognized Provider Burden During Hospital EMR Introduction.

2. Pedicle screw placement in the cervical vertebrae using augmented reality-head mounted displays: a cadaveric proof-of-concept study.

3. Beyond surface modification strategies to control infections associated with implanted biomaterials and devices - Addressing the opportunities offered by nanotechnology.

4. Necrotizing enterocolitis: a potential protective role for intestinal alkaline phosphatase as lipopolysaccharide detoxifying enzyme.

6. The role of intestinal alkaline phosphatase in the development of necrotizing enterocolitis.

7. Characterization of ion release from a novel biomaterial, Molybdenum-47.5Rhenium, in physiologic environments.

8. Hepatic Stellate Cell Targeting Using Peptide-Modified Biologicals.

9. Can a Spine Robot Be More Efficient and Less Expensive While Maintaining Accuracy?

10. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation.

11. Blood group AB is associated with poor outcomes in infants with necrotizing enterocolitis.

12. Role of Robotics in Adult Spinal Deformity.

13. From benchtop to clinic: a translational analysis of the immune response to submicron topography and its relevance to bone healing.

14. Phosphate Groups in the Lipid A Moiety Determine the Effects of LPS on Hepatic Stellate Cells: A Role for LPS-Dephosphorylating Activity in Liver Fibrosis.

15. A cadaveric precision and accuracy analysis of augmented reality-mediated percutaneous pedicle implant insertion.

16. Osteoprotegerin is More than a Possible Serum Marker in Liver Fibrosis: A Study into its Function in Human and Murine Liver.

17. Design of a Gene Panel to Expose the Versatile Role of Hepatic Stellate Cells in Human Liver Fibrosis.

18. The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor.

19. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.

20. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention.

21. Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver.

22. Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney.

23. Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E 2 in Liver Fibrosis Is Associated with Reduced Fibrogenesis.

24. WNT-5A regulates TGF-β-related activities in liver fibrosis.

25. Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice.

26. PGE2-treated macrophages inhibit development of allergic lung inflammation in mice.

28. Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma.

29. Precision-cut kidney slices (PCKS) to study development of renal fibrosis and efficacy of drug targeting ex vivo.

30. Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis.

31. Hepatic Localization of Macrophage Phenotypes during Fibrogenesis and Resolution of Fibrosis in Mice and Humans.

32. Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL).

33. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo.

34. New highlights for relaxin.

35. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.

36. Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver.

37. Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury.

38. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.

39. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth.

40. PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl₄-induced fibrogenesis in mice.

41. Drug targeting to the diseased liver.

42. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.

43. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.

44. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.

45. Antibody-free detection of protein tyrosine nitration in tissue sections.

47. Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice.

48. Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.

49. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.

50. Anatomic mapping of lumbar nerve roots during a direct lateral transpsoas approach to the spine: a cadaveric study.

Catalog

Books, media, physical & digital resources